Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US-12447171-B2 · Oct 21, 2025 · US
This page is not indexed by search engines while we improve data quality.
Macbeth Kyle patents
Macbeth Kyle is listed as an inventor on 25 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Macbeth Kyle |
| Total patents | 25 |
| First publication | Oct 27, 2016 |
| Latest publication | Oct 21, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-2023158009-A1 · May 25, 2023 · US
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-11590117-B2 · Feb 28, 2023 · US
Antiproliferative compounds and methods of use thereof
US-2022387413-A1 · Dec 8, 2022 · US
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US-2022249528-A1 · Aug 11, 2022 · US
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US-2022249529-A1 · Aug 11, 2022 · US
Antiproliferative compounds and methods of use thereof
US-11241423-B2 · Feb 8, 2022 · US
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US-2022003749-A1 · Jan 6, 2022 · US
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-2021154182-A1 · May 27, 2021 · US
Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
US-10996215-B2 · May 4, 2021 · US
Recent patents
Latest publications not already listed above.
Combination therapy for treating malignancies
US-10695352-B2 · Jun 30, 2020 · US
Antiproliferative compounds and methods of use thereof
US-2020163948-A1 · May 28, 2020 · US
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-2019175573-A1 · Jun 13, 2019 · US
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-10245258-B2 · Apr 2, 2019 · US
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-2019030018-A1 · Jan 31, 2019 · US
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US-2019004033-A1 · Jan 3, 2019 · US
Combination therapy for treating malignancies
US-2018303840-A1 · Oct 25, 2018 · US
Antiproliferative compounds and methods of use thereof
US-2018221361-A1 · Aug 9, 2018 · US
Antiproliferative compounds and methods of use thereof
US-9968596-B2 · May 15, 2018 · US
Antiproliferative compounds and methods of use thereof
US-2018021325-A1 · Jan 25, 2018 · US
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US-2017348298-A1 · Dec 7, 2017 · US
Antiproliferative compounds and methods of use thereof
US-9808451-B2 · Nov 7, 2017 · US
Antiproliferative compounds and methods of use thereof
US-2017007590-A1 · Jan 12, 2017 · US
Antiproliferative compounds and methods of use thereof
US-9499514-B2 · Nov 22, 2016 · US
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US-2016313300-A1 · Oct 27, 2016 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Celgene Corp | 23 |
| Agios Pharmaceuticals Inc | 2 |
| Celgene Quanticel Res Inc | 2 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/02 | 25 |
| A61K31/454 | 20 |
| A61P35/00 | 15 |
| A61K45/06 | 15 |
| A61K31/5377 | 13 |